PTCT · XBRL financial data

PTC Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PTCT's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26†Mar 31, 2026	Q2 FY26†Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	307*	210	187	197	213*	1,176	179	211	165*	273	361	358
Research and development	121*	116	132	161	125*	109	113	100	133*	101	99	105
Selling, general and administrative	76*	73	70	73	85*	81	85	84	97*	86	81	80
Total operating expenses	301*	256	227	251	376*	206	214	208	236*	228	212	333
Operating income (loss)	6*	(45)	(40)	(55)	(162)*	970	(35)	3	(71)*	45	149	25
Other income (expense)	19*	2	(2)	(2)	9*	(6)	(6)	7	(13)*	2	(3)	(1)
Income tax expense (benefit)	(1)*	7	13	9	(29)*	63	(6)	(39)	(4)*	0	14	11
Net income (loss)	(156)*	(92)	(99)	(107)	(66)*	867	(65)	16	(135)*	(3)	83	(52)
Earnings per share, basic USD per share	(2.06)*	(1.20)	(1.29)	(1.39)	(0.85)*	11.09	(0.83)	0.20	(1.62)*	(0.03)	1.01	(0.62)
Earnings per share, diluted USD per share	(2.06)*	(1.20)	(1.29)	(1.39)	(0.85)*	10.04	(0.83)	0.20	(1.33)*	(0.03)	0.92	(0.62)
Weighted average shares, basic millions of shares	75*	76	77	77	77*	78	78	78	83*	83	83	83
Weighted average shares, diluted millions of shares	75*	76	77	77	77*	86	78	87	101*	83	92	83

† Share count changed about 1/10 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 10x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (PTCT's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26†Mar 31, 2026	Q2 FY26†Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	594	548	655	526	780	1,480	1,017	673	985	834	1,050	509
Marketable securities	283	336	439	487	360	547	972	1,015	961	1,058	1,179	1,619
Inventory	31	30	32	36	23	22	34	53	80	76	91	109
Prepaid and other current assets	150	56	46	33	44	57	54	64	67	66	58	62
Total current assets	1,219	1,169	1,358	1,282	1,366	2,316	2,273	2,008	2,274	2,254	2,617	2,538
Property and equipment, net	87	93	66	63	61	59	57	57	55	53	51	49
Right-of-use asset	92	91	57	59	57	57	56	81	80	77	75	73
Goodwill	82	82	82	82	82	82	82	82	82	82	82	82
Total assets	1,896	1,790	1,916	1,842	1,705	2,655	2,634	2,644	2,899	2,869	3,250	3,208
Accounts payable	6	27	24	13	17	15	27	37	45	25	40	42
Current portion of long-term debt	—	—	—	—	—	—	—	286	287	287	55	—
Total current liabilities	603	575	610	611	581	595	628	866	968	924	771	776
Long-term debt	284	285	285	285	285	286	286	—	—	—	536	536
Lease liability, non-current	98	105	79	83	75	74	71	95	94	90	88	86
Total liabilities	2,714	2,684	2,897	2,897	2,803	2,841	2,841	2,799	3,104	3,050	3,416	3,399
Accumulated deficit	(3,284)	(3,375)	(3,474)	(3,581)	(3,647)	(2,780)	(2,845)	(2,829)	(2,964)	(2,967)	(2,884)	(2,935)
Total stockholders' equity	(819)	(894)	(980)	(1,054)	(1,098)	(186)	(207)	(156)	(205)	(180)	(165)	(191)
Total liabilities and equity	1,896	1,790	1,916	1,842	1,705	2,655	2,634	2,644	2,899	2,869	3,250	3,208
Common shares outstanding (cover page) millions of shares	77	77	77	77	79	79	79	80	83	8	83	84

† Share count changed about 1/10 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 10x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (PTCT's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26†Mar 31, 2026	Q2 FY26†Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(156)*	(92)	(99)	(107)	(66)*	867	(65)	16	(135)*	(3)	83	(52)
Stock-based compensation	17*	18	19*	20*	17*	18	19*	19*	19*	23	23*	24*
Depreciation and amortization	81*	55	7*	6*	7*	7	8*	11*	13*	15	16*	17*
Net cash from operating activities	(100)*	71	(71)*	(77)*	(30)*	870	(58)*	(66)*	(34)*	(59)	129*	(25)*
Purchases of property and equipment	6*	10	(7)*	1*	4*	2	1*	3*	2*	1	2*	3*
Net cash from investing activities	(94)*	(115)	(66)*	(43)*	268*	(184)	(422)*	(290)*	34*	(94)	(123)*	(442)*
Net cash from financing activities	620*	1	246*	(18)*	26*	9	4*	15*	303*	6	212*	(73)*
Net change in cash	429*	(46)	104*	(129)*	256*	701	(463)*	(347)*	312*	(148)	216*	(541)*

† Share count changed about 1/10 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 10x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
PTC Therapeutics	509	358	(25)*	83.5M	—	Q3 FY26 10-QSep 30, 2026
Inhibitor Therapeutics	0.5	not reported	(0.8)*	173.8M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Integrated Biopharma	4.5	not reported	(1.2)*	31.1M	3.7 quarters	Q4 FY26 10-KJun 30, 2026
Oragenics	3.9	not reported	(2.2)*	4.5M	1.8 quarters	Q2 FY26 10-QJun 30, 2026
Enveric Biosciences	8.3	not reported	(2.4)*	4.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Polomar Health Services	0.2	1.5	0.1*	28.4M	—	Q2 FY26 10-QJun 30, 2026
Q/C Technologies	0.3	not reported	(1.8)*	8.2M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
MetaVia	13	not reported	(3.8)*	6.6M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Jaguar Health	3.8	1.2	(5.3)*	not reported	0.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.